NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of…
--Phase 1 clinical trial will evaluate safety and immunogenicity of several formulations of SCB-2020S as a 2-dose vaccination series in…
VANCOUVER, British Columbia., May 31, 2022 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure…
NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech…
London, United Kingdom, May 31, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”), an innovative biotechnology…
MIAMI, May 31, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for…
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development…
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of…
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics Dotinurad (URECE®…